SHATTUCK LABS INC (STTK)
Health Care · Clinical-stage monoclonal antibody therapeutics · NASDAQ
A clinical-stage biotech pioneering potentially first-in-class DR3 blocking antibodies to treat inflammatory bowel disease and other immune-mediated diseases.
What SHATTUCK LABS INC does
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases. The company's lead program, SL-325, is a high-affinity DR3 blocking monoclonal antibody designed to achieve more complete blockade of the DR3/TL1A pathway compared to TL1A blocking antibodies currently in development. The company believes its DR3-targeting approach offers potential advantages in clinical remission rates, durability of effect, and a superior immunogenicity profile versus competing TL1A blockers.
Themes: ["Inflammatory bowel disease (IBD) / Crohn's disease","Immune-mediated diseases","DR3 receptor antagonism","Monoclonal antibodies","TNF receptor pathway"]
Fundamentals
- Price$7.03 as of 2026-07-09 close
- Market cap$635M as of 2026-07-10
- 1-year return+750.0% as of 2026-07-09 close
- Net margin-1005.6% as of 2026-07-10
- ROE-60.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-78.3% as of 2026-07-10
- Revenue CAGR (3y)+15.3% SEC XBRL
- Beta1.00 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial execution risk: ability to enroll patients and successfully complete Phase 2 trial in Crohn's disease initiating Q3 2026; timing and likelihood of regulatory approvals remain uncertain","Manufacturing and supply risk: ability to manufacture and supply SL-325 for clinical trials and commercial use if approved, including impact of inflationary pressures on R&D and manufacturing costs","Competitive and market risk: competing TL1A blocking antibodies (afimkibart, tulisokibart, duvakitug) are already in clinical development; company must establish superiority of DR3 blocking approach; pricing, coverage, and reimbursement uncertainties for approved products"]
Competitors & peers
- Genentech (Roche) - TL1A blocking antibodies in clinical development
- Ionis Pharmaceuticals - TNF pathway targeting
- AbbVie (ABBV) - inflammatory bowel disease therapeutics
- Janssen Biotech - IBD and immune-mediated disease treatments
- Pfizer (PFE) - TNF and immune pathway inhibitors
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.